FDA supplemental approval: Arsenic Trioxide (Labeling)

AI Summary

This record documents an FDA supplemental approval for a labeling change to arsenic trioxide injectables (1 mg/mL and 2 mg/mL formulations) by Zydus Pharmaceuticals, approved on 2 June 2026. The record itself does not contain clinical trial results, efficacy data, or safety findings; it is purely a regulatory action indicating that a labeling modification was accepted by the FDA.

Plain-language summary

This is an FDA supplemental approval action for labeling of arsenic trioxide; it documents a regulatory decision, not clinical trial evidence or efficacy data.

Reported figures

Quoted from the source exactly as published.

Caveats

• This record does not contain clinical trial results, efficacy endpoints, safety data, or comparative effectiveness information.
• The specific nature of the labeling change is not described in this record.
• No patient population, sample size, or clinical outcomes are reported.
• This approval does not imply evidence of clinical benefit; it documents only that a labeling modification was accepted by the FDA.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.